Edwards' heart valve shows long-term promise
This article was originally published in Clinica
Edwards Lifesciences says that it has become the first company to provide long-term data to show that its pericardial tissue heart valve continues to provide haemodynamic stability 17 years after implantation. The results add to previously reported 17-year data demonstrating the product's long-term durability, says the Irvine, California firm.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.